ClinicalTrials.gg
CompletedNCT00746733Updated Jun 14, 2021Results posted

Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC

A Phase 1 interventional study of Lisdexamfetamine Dimesylate and Adderall XR (mixed salts amphetamine) in Healthy Volunteers, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to determine if taking Vyvanse with Prilosec OTC or Adderall XR with Prilosec OTC changes how quickly the drug is absorbed into the body and/or changes how much of the drug is absorbed into the body.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug
  • Interaction
  • Study
03

In context

Lead sponsor

Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.

Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.

First submitted before Shire became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers, age 18 to 45 inclusive at the time of consent.
  2. Male, or non-pregnant, non-lactating female
  3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening, and a negative urine pregnancy test on Day -1 after checking into the clinic the day before the first dose of product.
  4. (BMI) between 20.0 and 30.0 kg/m² inclusive. This inclusion criterion will only be assessed at the first screening visit.
  5. Satisfactory medical assessment with no significant or relevant abnormality in medical history, physical examination (PE), vital signs and laboratory evaluation
  6. Normal or clinically insignificant Screening findings as assessed by the Investigator.
  7. Ability to swallow investigational products.

Exclusion criteria

Exclusion Criteria:

  1. Current or recurrent disease that could affect the action, absorption or disposition of the products, or could affect clinical or laboratory assessments.
  2. Current or relevant previous history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational products or study procedures.
  3. Significant illness, as judged by the Investigator, within 2 weeks of the first dose of investigational product.
  4. History of significant anxiety, tension or agitation as assessed by the Investigator.
  5. History of or current diagnosis of glaucoma.
  6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
  7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  8. History of controlled or uncontrolled hypertension or a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg.
  9. Known family history of sudden cardiac death or ventricular arrhythmia.
  10. Currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation.
  11. Current use of any medication (including prescription, over the counter [OTC], herbal or homeopathic preparations) with the exception of hormonal replacement therapy or hormonal (Current use is defined as use within 14 days of first dose of investigational product).
  12. Use of any medication known to inhibit or induce the CYP450 enzymes responsible for the metabolism of the investigational products within 14 days of first dose of investigational product.
  13. Known or suspected intolerance or to the investigational product(s), closely related compounds or any of the stated ingredients.
  14. History of alcohol or other substance abuse within the last year.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Vyvanse (LDX)

    Drug: Lisdexamfetamine Dimesylate

  • Experimental
    Adderall XR (AXR)

    Drug: Adderall XR (mixed salts amphetamine)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  2. Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  3. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  4. Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  5. Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  6. Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  7. AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    Time frame: 0 through 96 hours after dosing

  8. T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

    Time frame: 0 through 96 hours after dosing

  9. Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    Total amphetamine is the d- and l-amphetamines.

    Time frame: 0 through 96 hours after dosing

  10. Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    Total amphetamine is the d- and l-amphetamines.

    Time frame: 0 through 96 hours after dosing

  11. AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    Total amphetamine is the d- and l-amphetamines.

    Time frame: 0 through 96 hours after dosing

  12. T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

    Total amphetamine is the d- and l-amphetamines.

    Time frame: 0 through 96 hours after dosing

Secondary outcomes

  1. Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.

    Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

  2. DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC

    Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

  3. DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC

    Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

    Time frame: Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing

  4. Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    Time frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

  5. Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    Time frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

  6. Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    Time frame: Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing

  7. Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

    QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.

    Time frame: Pre-dose, 2 and 8 hours after dosing

07

Results

Posted Nov 17, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneVyvanse FirstAdderall XR First
Started1212
Completed1212
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneVyvanse FirstAdderall XR First
Started1212
Completed1112
Not completed10
Withdrew: Adverse event10
Third Intervention
Participant flow — Third Intervention
MilestoneVyvanse FirstAdderall XR First
Started1112
Completed1011
Not completed11
Withdrew: Withdrawal by subject11
Fourth Intervention
Participant flow — Fourth Intervention
MilestoneVyvanse FirstAdderall XR First
Started1011
Completed1011
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
ng/mlVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Maximum Plasma Concentration (Cmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC45.04 ± 13.97128.66 ± 7.17446.34 ± 9.71029.97 ± 5.719
SecondaryDrug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.

Question 2: How much do you like the effects you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
Reported as:
Mean · units on a scale
Drug Rating Questionnaire-Subject (DRQ-S), Question 2, for Vyvanse and Adderall XR in Combination With Prilosec OTC.
units on a scaleVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose1.0 ± 0.01.0 ± 0.0
0.5 h1.2 ± 0.602.0 ± 3.09
1 h1.8 ± 1.752.0 ± 3.08
1.5 h4.6 ± 8.282.2 ± 3.56
2 h4.6 ± 8.332.5 ± 4.56
2.5 h3.9 ± 6.042.3 ± 3.73
3 h3.5 ± 5.781.5 ± 1.03
3.5 h2.7 ± 3.781.3 ± 0.80
4 h1.7 ± 1.061.4 ± 0.86
5 h2.4 ± 3.931.3 ± 0.72
6 h1.4 ± 0.811.2 ± 0.51
8 h1.4 ± 0.741.3 ± 1.32
12 h1.2 ± 0.621.1 ± 0.36
24 h1.3 ± 0.721.0 ± 0.22
SecondaryDRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC

Question 1: How much do you feel the drug now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
Reported as:
Mean · units on a scale
DRQ-S, Question 1, for Vyvanse and Adderall XR in Combination With Prilosec OTC
units on a scaleVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose1.0 ± 0.01.0 ± 0.0
0.5 h1.3 ± 0.731.3 ± 0.66
1 h2.1 ± 2.661.9 ± 2.46
1.5 h5.2 ± 8.382.3 ± 2.97
2 h6.0 ± 8.693.5 ± 5.33
2.5 h6.0 ± 7.593.5 ± 4.64
3 h5.3 ± 6.722.7 ± 3.36
3.5 h4.9 ± 6.092.1 ± 2.01
4 h3.8 ± 4.572.1 ± 1.84
5 h3.1 ± 4.131.9 ± 1.74
6 h3.4 ± 3.601.5 ± 0.87
8 h3.0 ± 4.261.3 ± 0.66
12 h4.4 ± 7.191.2 ± 0.54
24 h1.6 ± 1.401.0 ± 0.22
SecondaryDRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC

Question 3: Do you dislike the drug effect you are feeling now? Questions are rated on a 29-point scale from 1 (not at all) to 29 (an awful lot). The higher the score the stronger the subjective experience. This is a subjective measure of a drug's effect that has been used to assess the abuse potential of drugs.

Time frame:
Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12 and 24 hours after dosing
Reported as:
Mean · units on a scale
DRQ-S, Question 3, for Vyvanse and Adderall XR in Combination With Prilosec OTC
units on a scaleVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose1.0 ± 0.01.0 ± 0.0
0.5 h2.0 ± 3.492.1 ± 3.11
1 h1.8 ± 1.672.0 ± 3.08
1.5 h4.3 ± 8.031.8 ± 1.55
2 h4.5 ± 8.371.4 ± 0.93
2.5 h3.8 ± 6.391.4 ± 0.80
3 h3.4 ± 5.781.2 ± 0.54
3.5 h2.6 ± 3.541.3 ± 0.72
4 h1.8 ± 1.181.3 ± 0.80
5 h2.3 ± 4.131.3 ± 0.97
6 h1.6 ± 1.021.2 ± 0.70
8 h1.6 ± 1.781.1 ± 0.48
12 h1.3 ± 0.801.2 ± 0.51
24 h1.1 ± 0.481.0 ± 0.22
SecondarySystolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time frame:
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
Reported as:
Mean · mmHg
Systolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
mmHgVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose115.6 ± 10.79115.3 ± 10.26114.8 ± 11.29113.9 ± 11.71
1 h122.8 ± 11.10121.0 ± 10.46121.7 ± 13.31122.6 ± 9.67
2 h127.9 ± 12.81122.2 ± 11.34125.5 ± 10.14124.7 ± 12.74
4 h127.6 ± 12.95120.8 ± 11.71125.2 ± 11.50124.2 ± 9.75
8 h126.0 ± 12.69122.4 ± 11.04123.5 ± 13.25119.2 ± 10.99
12 h123.4 ± 15.62121.9 ± 12.04122.2 ± 13.19118.4 ± 10.58
24 h114.0 ± 11.68118.1 ± 12.97114.7 ± 11.19115.6 ± 13.42
48 h114.6 ± 12.84112.6 ± 10.56114.4 ± 10.81113.6 ± 11.01
72 h113.7 ± 10.25114.8 ± 11.81115.1 ± 11.71116.0 ± 9.74
96 h114.0 ± 10.53114.5 ± 10.72114.8 ± 11.06116.1 ± 9.29
PrimaryTime of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
hVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Time of Maximum Plasma Concentration (Tmax) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC3.5 ± 1.145.2 ± 3.103.5 ± 0.973.3 ± 1.45
PrimaryArea Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng.h/ml
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
ng.h/mlVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Area Under the Steady-state Plasma Concentration-time Curve (AUC) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC626.27 ± 198.982473.70 ± 71.043687.00 ± 196.906472.35 ± 108.891
PrimaryTerminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

d-Amphetamine is an isomer of Vyvanse and Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
hVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Terminal Half-life (T 1/2) of d-Amphetamine for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC9.7 ± 1.5510.25 ± 1.3610.4 ± 1.6510.91 ± 1.95
SecondaryDiastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time frame:
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
Reported as:
Mean · mmHg
Diastolic Blood Pressure for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
mmHgVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose76.0 ± 6.6874.1 ± 6.7277.7 ± 8.6075.8 ± 7.80
1 h79.2 ± 6.6276.4 ± 5.9880.5 ± 9.5280.4 ± 6.29
2 h79.0 ± 6.9775.4 ± 6.5882.0 ± 6.4481.9 ± 8.71
4 h79.9 ± 7.9177.7 ± 6.3182.0 ± 7.6882.0 ± 7.09
8 h78.6 ± 7.8774.1 ± 5.7380.3 ± 9.5479.2 ± 7.96
12 h79.6 ± 9.4578.5 ± 8.2978.7 ± 10.4777.8 ± 8.20
24 h75.9 ± 6.7676.8 ± 8.6275.0 ± 7.7675.4 ± 7.30
48 h74.5 ± 8.3973.5 ± 8.4077.2 ± 6.5374.4 ± 8.01
72 h75.1 ± 7.9774.7 ± 7.2476.1 ± 7.5877.9 ± 6.77
96 h74.5 ± 8.0275.7 ± 7.6575.7 ± 7.4878.3 ± 6.96
SecondaryPulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
Time frame:
Pre-dose and 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours after dosing
Reported as:
Mean · bpm
Pulse Rate for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
bpmVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose70.9 ± 9.8769.0 ± 8.8773.3 ± 10.1671.4 ± 10.14
1 h69.7 ± 10.6170.0 ± 11.2973.4 ± 10.9173.8 ± 13.78
2 h78.2 ± 11.6475.2 ± 10.8583.4 ± 14.6880.5 ± 16.87
4 h79.0 ± 14.4074.5 ± 12.6284.4 ± 16.2978.4 ± 15.03
8 h84.8 ± 11.3879.1 ± 10.7087.7 ± 14.3481.5 ± 11.50
12 h86.4 ± 13.8482.3 ± 14.1289.1 ± 13.7782.7 ± 10.99
24 h79.9 ± 11.1974.7 ± 12.5880.4 ± 11.3276.4 ± 12.06
48 h73.2 ± 11.2874.0 ± 11.0275.1 ± 10.3275.0 ± 9.46
72 h72.2 ± 10.6373.3 ± 9.1672.0 ± 7.9972.7 ± 8.78
96 h70.7 ± 10.6470.4 ± 9.1172.5 ± 10.1273.9 ± 9.86
SecondaryElectrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC

QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation.

Time frame:
Pre-dose, 2 and 8 hours after dosing
Reported as:
Mean · msec
Electrocardiogram Results (QTcF Interval) for Vyvanse and Adderall XR Alone and in Combination With Prilosec OTC
msecVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
Pre-dose399.8 ± 14.55398.3 ± 15.24399.3 ± 13.38399.8 ± 15.04
2 h395.0 ± 14.11394.6 ± 13.42397.9 ± 13.86396.1 ± 14.49
8 h390.0 ± 12.45393.8 ± 13.94395.4 ± 14.93394.4 ± 13.26
PrimaryCmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng/ml
Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
ng/mlAdderall XRAdderall XR + Prilosec OTC
Cmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC7.91 ± 2.0228.10 ± 1.632
PrimaryTmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
hAdderall XRAdderall XR + Prilosec OTC
Tmax of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC5.6 ± 3.03.5 ± 1.74
PrimaryAUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng.h/ml
AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
ng.h/mlAdderall XRAdderall XR + Prilosec OTC
AUC of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC145.28 ± 24.355145.83 ± 38.233
PrimaryT 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

l-Amphetamine is an isomer of Adderall XR and is an active form that is responsible for the drug's therapeutic activity.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
hAdderall XRAdderall XR + Prilosec OTC
T 1/2 of l-Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC11.98 ± 1.9213.06 ± 2.63
PrimaryCmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng/ml
Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
ng/mlAdderall XRAdderall XR + Prilosec OTC
Cmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC36.56 ± 9.18838.05 ± 7.351
PrimaryTmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
hAdderall XRAdderall XR + Prilosec OTC
Tmax of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC5.30 ± 3.073.29 ± 1.45
PrimaryAUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · ng.h/ml
AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
ng.h/mlAdderall XRAdderall XR + Prilosec OTC
AUC of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC620.68 ± 95.689620.91 ± 145.378
PrimaryT 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC

Total amphetamine is the d- and l-amphetamines.

Time frame:
0 through 96 hours after dosing
Reported as:
Mean · h
T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC
hAdderall XRAdderall XR + Prilosec OTC
T 1/2 of Total Amphetamine for Adderall XR Alone and in Combination With Prilosec OTC10.38 ± 1.5611.05 ± 2.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vyvanse—0/24 (0%)8/24 (33.3%)
Adderall XR—0/23 (0%)3/23 (13%)
Vyvanse + Prilosec OTC—0/21 (0%)10/21 (47.6%)
Adderall XR + Prilosec OTC—0/21 (0%)3/21 (14.3%)
Most frequent other events
Most frequent other events
EventVyvanseAdderall XRVyvanse + Prilosec OTCAdderall XR + Prilosec OTC
AnxietyPsychiatric disorders2/242/238/210/21
VasospasmVascular disorders0/240/234/213/21
HeadacheNervous system disorders1/240/233/210/21
DizzinessNervous system disorders1/240/232/210/21
PalpitationsCardiac disorders2/241/230/210/21
TachycardiaCardiac disorders2/240/230/210/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Entire Study Population
<=18 years0
Between 18 and 65 years24
>=65 years0
Age, Continuous
Age, Continuous(years)Entire Study Population
Mean37.7 ± 6.54
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female6
Male18
Region of Enrollment
Region of Enrollment(Participants)Entire Study Population
United States24
08

Study locations

1 site
  • Clinical Pharmacology of Miami, Inc.
    Miami, Florida 33014, United States
09

References and documents

Publications

  • Haffey MB, Buckwalter M, Zhang P, Homolka R, Martin P, Lasseter KC, Ermer JC. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med. 2009 Sep;121(5):11-9. doi: 10.3810/pgm.2009.09.2048. PubMed 19820270 ↗
  • Wigal T, Brams M, Gasior M, Gao J, Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med. 2011 Mar;123(2):169-76. doi: 10.3810/pgm.2011.03.2275. PubMed 21474905 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2008 to primary completion in Oct 2008, 1 month.

Results were first posted in Nov 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 4, 2008
StartActual
Sep 8, 2008
Primary completionActual
Oct 26, 2008
CompletionActual
Oct 26, 2008
Results first posted
Nov 17, 2009
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00746733
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
Sep 8, 2008
Primary completion
Oct 26, 2008
Completion
Oct 26, 2008
Results posted
Nov 17, 2009
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lisdexamfetamine · Adderall

Start the discussion